SynthesisFrontiers in immunology2026
Identification of
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pediatric steroid-sensitive nephrotic syndrome (pSSNS) is a common childhood glomerular disorder characterized by corticosteroid responsiveness, yet frequent relapses and steroid dependence lead to long-term complications. While GWAS have identified genetic risk loci for pSSNS, its shared genetic architecture with immune-mediated glomerulopathies like IgA nephropathy (IgAN) remains unclear. Methods: We performed integrative genetic analyses combining GWAS data from pSSNS (2,440 cases/36,023 controls) and IgAN (10,146 cases/28,751 controls) through meta-analysis and conjunctional false discovery rate (conjFDR) approaches. Findings were replicated in an independent Chinese pSSNS cohort (501 cases/2,506 controls). Transcriptomic profiling of peripheral blood and renal tissues, supplemented by single-cell RNA sequencing, elucidated molecular mechanisms. Results: Meta-analysis identified nine genome-wide significant loci (P < 5×10 Discussion: Our study establishes IL7R as a key shared genetic risk locus in pSSNS and IgAN, supported by multi-omics evidence of immune cell-specific dysregulation. These findings implicate IL7R-mediated T cell homeostasis in the pathogenesis of both disorders, nominating this pathway for targeted therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.